ArticleCurrent microbiology2026
Berberine Hydrochloride Enhances the Fluconazole Susceptibility of Candida albicans through Multiple Targets.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Candida albicans is ubiquitous on human mucosal surfaces and easy to cause infectious diseases. The widespread use of antifungal drugs has led to the increasing drug resistance of C. albicans, posing a significant challenge to clinical treatment. Berberine hydrochloride (BBH), a quaternary ammonium alkaloid isolated from Coptidis Rhizoma, exhibits broad-spectrum antifungal activity. This study explored the antifungal effect and mechanism of BBH combined with fluconazole (FLC) against drug-resistant C. albicans. Results showed that BBH could enhance the antifungal effect of FLC against the drug-resistant C. albicans. Additionally, BBH combined with FLC significantly disrupted the cell wall integrity, inhibited the formation of biofilms and hyphae, and increased the ROS levels. Transcriptome sequencing further elucidated the inhibitory mechanism of BBH combined with FLC against drug-resistant C. albicans, which primarily by affecting metabolic pathways such as cell wall biosynthesis, superoxide metabolism, and monooxygenase activity. Key genes associated with these pathways, including CHS1, SUN41, CTA1, SOD5, and HWP1, were significantly downregulated. This study primarily reveals that BBH combined with FLC exhibits significant antifungal effects against drug-resistant C. albicans. This provides new therapeutic insights and potential drug combination schemes for clinical treatment of drug-resistant C. albicans infections.
Indexed as
Identifiers
41896451What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.